Traveling has always come with complications, but the coronavirus pandemic has made it more challenging than ever.

Nevada knows how to put on a good show. But in a year of buzzy U.S. Senate races, the Silver State is far from the top of the list.

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.

After declining for 10 straight weeks, COVID-19 hospitalizations plateaued in Clark County this week and inched up statewide, according to new state data released Wednesday.

The psychological impact of the October 1 shooting five years ago will never be fully measured.

Even as Republican candidates continue to pummel incumbent Democrats on a faltering economy and sidestep anger over the overturning of Roe v. Wade, they have launched a fresh salvo of attacks over immigration.

An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

New observations are challenging a hypothesis about what produces these energetic bursts of radio waves.